# The Role of Pioglitazone in Vascular Transcriptional Remodeling

> **NCT05775380** · PHASE4 · UNKNOWN · sponsor: **University of Campinas, Brazil** · enrollment: 20 (estimated)

## Conditions studied

- Myocardial Reperfusion Injury

## Interventions

- **DRUG:** Pioglitazone 45 mg

## Key facts

- **NCT ID:** NCT05775380
- **Lead sponsor:** University of Campinas, Brazil
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-15
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-12-22
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775380, "The Role of Pioglitazone in Vascular Transcriptional Remodeling". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT05775380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*